Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.
Research
Disorders due to substance use: Hallucinogens and MDMA-related substances (read).
MDMA-assisted therapy for borderline personality disorder (read).
Unintentional ketamine overdose via telehealth (read).
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder (read).
UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study (read).
Commentary: “ARC: a framework for access, reciprocity and conduct in psychedelic therapies” (read).
Gilgamesh Pharmaceuticals' first peer-reviewed publication for GM-1020, an oral ketamine analog designed for reduced dissociative/sedative properties potentially suitable for at-home use (read).
Beckley Foundation’s report on “Reversing The Exploitation ...